acylated peptide raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-08-30. Anything still debated is marked as such rather than presented as settled.
Serum protein binding dominates the pharmacokinetic profile. The attached chain associates strongly with albumin, shielding the peptide from enzymatic attack and slowing filtration by the kidney. This interaction extends the circulation half-life to roughly one week in humans, which supports weekly administration intervals. An oral version pairs the peptide with an absorption enhancer that transiently alters gastric epithelium, permitting limited uptake; bioavailability by that route is substantially lower than by injection.
Semaglutide belongs to the glucagon-like peptide-1 receptor agonist class, a group of synthetic peptides that imitate an incretin hormone released by intestinal L cells after food intake. Native GLP-1 circulates for only a few minutes because dipeptidyl peptidase-4 cleaves it rapidly. The hormone acts on pancreatic islets, the gastrointestinal tract, and several brain regions. Because the natural peptide is short-lived, development work concentrated on analogues that keep receptor activity while resisting enzymatic breakdown and renal clearance.
Two structural features account for the prolonged half-life of semaglutide. A modified amino acid at position 8 resists cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GLP-1. A fatty diacid side chain binds serum albumin, which limits renal clearance and protects the peptide from enzymatic breakdown. These modifications yield a plasma half-life of approximately one week in humans, allowing once-weekly administration. The relationship between plasma concentration and clinical effect varies between individuals, and sources of that variability are still being characterized.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1 (GLP-1), a hormone released from intestinal L-cells after food intake. The compound belongs to the incretin mimetic class and acts at GLP-1 receptors distributed across pancreatic, gastrointestinal, cardiovascular, and central nervous system tissues. Compared with native GLP-1, the molecule carries structural changes that extend its activity from minutes to roughly one week. It is studied for glycemic control in type 2 diabetes and for weight management, and its effects on cardiovascular and other outcomes remain active research areas.
Receptor binding triggers G protein signaling that raises intracellular cyclic AMP in pancreatic beta cells. Insulin release follows in a glucose-dependent manner, so secretion increases when blood glucose is elevated and diminishes when it is not. The same signaling suppresses glucagon release from alpha cells and slows gastric emptying, which blunts the post-meal glucose rise. In the brain, receptor activation in regions such as the arcuate nucleus is associated with reduced appetite and lower energy intake. How much each of these effects contributes to overall weight change is not fully settled.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide, GLP-1 receptor agonist | 31 amino acid residues |
| Molecular formula | C187H291N45O59 | free peptide, no counter-ion |
| Approximate mass | 4114 Da | matches theoretical value |
| Receptor target | Glucagon-like peptide-1 receptor | Gs-coupled, cyclic AMP pathway |
| Circulation half-life | About one week in humans | extended by albumin association |
Receptor activation follows the canonical Gs pathway: binding increases intracellular cyclic AMP, which promotes protein kinase A activity. In pancreatic beta cells this amplifies glucose-dependent insulin release, so secretion rises when blood glucose is high and changes little when it is low. The same signalling suppresses glucagon release from alpha cells and slows gastric emptying. Receptors in the hypothalamus and brainstem are thought to contribute to reduced appetite and lower energy intake. Which of these effects dominates clinical outcomes remains an area of active study.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released by intestinal L cells after food intake. The natural hormone acts on pancreatic and central receptors but is degraded within minutes by dipeptidyl peptidase-4 and other peptidases. Semaglutide belongs to the class of long-acting GLP-1 receptor agonists, a group distinguished by structural changes that slow breakdown and extend circulation time. Its development followed earlier short-acting analogues and reflects a general strategy in peptide drug design: preserve receptor activity while blocking proteolytic clearance.
Three structural changes define the molecule. At position 8 an alpha-aminoisobutyric acid residue replaces alanine, which blocks dipeptidyl peptidase-4 cleavage. At position 34 arginine replaces lysine, and at position 26 a lysine carries a C18 fatty diacid attached through a short linker. The fatty chain binds serum albumin, and this albumin association reduces renal filtration and enzymatic attack. The unchanged backbone retains the receptor contacts that produce signalling. The free base has the formula C187H291N45O59 and a molecular weight near 4114 daltons.
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released after nutrient intake. The molecule contains 31 amino acid residues and differs from the native sequence at several positions. A non-natural residue at position eight resists the enzyme that normally truncates the hormone, while a lysine-linked fatty diacid side chain promotes binding to serum albumin. These two modifications extend the circulating half-life from minutes to roughly one week. The peptide is produced by solid-phase synthesis followed by selective acylation, and its identity and purity are confirmed by spectrometric and chromatographic techniques.
The primary target is the GLP-1 receptor, a class B G protein-coupled receptor expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises intracellular cyclic AMP, which potentiates glucose-dependent insulin secretion and lowers glucagon release when blood glucose is elevated. Signalling in the hypothalamus and brainstem is associated with reduced appetite and slower gastric emptying. Because the insulinotropic effect depends on prevailing glucose levels, the hypoglycaemic risk of the peptide alone is described as low in most study settings. The relative contribution of peripheral and central actions remains an active research question.
By the late 1930s, Thomas was embraced as the "poetic herald" for a group of English poets, the New Apocalyptics. Thomas refused to align himself with them and declined to sign their manifesto. He later stated that he believed they were "intellectual muckpots leaning on a theory". Despite this, many of the group, including Henry Treece, modelled their work on Thomas's. In the politically charged atmosphere of the 1930s Thomas's sympathies were very much with the radical left, to the point of his holding close links with the communists; he was also decidedly pacifist and anti-fascist. He was a supporter of the left-wing No More War Movement and boasted about participating in demonstrations against the British Union of Fascists. Bert Trick has provided an extensive account of an Oswald Mosley rally in the Plaza cinema in Swansea in July 1933 that he and Thomas attended.
The Tatra Shepherd Dog (Polish: Polski Owczarek Podhalański, lit. 'Polish Podhale Sheepdog') is a Polish breed of large flock guardian dog originating in the Tatra Mountains of the Podhale region of southern Poland. It was fully recognised by the Fédération Cynologique Internationale in 1963. It is one of five dog breeds originating in Poland, the others being the Polish Greyhound, the Polish Hound, the Polish Hunting Dog and the Polish Lowland Sheepdog.
==== Zonal necrosis ==== This is the most common type of drug-induced liver cell necrosis where the injury is largely confined to a particular zone of the liver lobule. It may manifest as a very high level of ALT and severe disturbance of liver function leading to acute liver failure.
Spain also made history by being the first nation to become the reigning champion for both the men's and women's World Cups, and the first team to win the World Cup while conceding only one goal during the tournament. France captain Kylian Mbappé won his second consecutive Golden Boot for scoring the most goals (10) during the tournament. He became the all-time leading goalscorer at the World Cup and the first player to win multiple World Cup Golden Boots. The average number of goals per match in the tournament was 2.96, the highest since the 1970 edition. Spain captain Rodri won the Golden Ball as the best player of the tournament. Unai Simón won the Golden Glove as the tournament's best goalkeeper, while Pau Cubarsí won the Young Player Award as the tournament's best young player. Nearly 7 million people attended matches during the tournament, surpassing the 1994 edition to set a new record for the highest attendance in World Cup history. The 2026 World Cup reportedly generated a record $15 billion in revenue.
=== Lawsuit === Fenn's work with electrospray ionization was at the center of a lawsuit pitting him against his alma mater and former employer, Yale University. His initial dispute with the university began in 1987, when he turned 70 – Yale's mandatory retirement age. Per university policy, Fenn was made an emeritus professor, which resulted in a reduction to his lab space. Emeritus professors at Yale are still provided with an office, but cannot conduct their own research, nor manage their own labs. In 1989, when Yale University inquired about the progress and potential about his electrospray work, he downplayed its potential scientific and commercial value. Fenn believed he had the rights to the invention under the Bayh–Dole Act. Fenn patented the technology on his own, and sold licensing rights to a company he partly owned – Analytica of Branford. In 1993, a private company seeking to license the use of electrospray technology traced its invention to Yale, when the university discovered that Fenn held the patent. Yale's policy regarding patents generated by faculty or students requires that a percentage of any royalties generated from the patent are used by the university to fund future research. They do not claim the rights to patents that are produced away from university facilities or not related to the researcher's "designated activities." Fenn claimed that he owned the technology because the work was completed after he had been forced to downsize at the university's mandatory retirement age.
Sources: en.wikipedia.org
It can also cause sexual side effects, galactorrhoea, infertility, gynecomastia, and, with chronic use, reduced bone mineral density leading to breaks, all of which are associated with increased prolactin secretion. Alpha α1 adrenergic receptors: This action accounts for the orthostatic hypotensive effects and perhaps some of the sedating effects of risperidone. Alpha α2 adrenergic receptors: Risperidone's action at these receptors may cause greater positive, negative, affective, and cognitive symptom control. Histamine H1 receptors: effects on these receptors account for its sedation and reduction in vigilance. This may also lead to drowsiness and weight gain. 5-HT2A receptor: Risperidone’s atypicality is relatively strong in terms of its binding preference for 5-HT2A receptors over dopamine D2 receptors. However, clozapine is generally considered stronger in this regard. Clozapine differs in that it has lower overall receptor affinity compared to some other atypical antipsychotics, but still maintains an approximate 4-fold higher affinity for 5-HT2A receptors relative to D2 receptors. Among three atypical antipsychotics often noted for significant 5-HT2A receptor blockade (risperidone, olanzapine, and clozapine), risperidone shows the highest degree of receptor occupancy in a dose-dependent comparison. At approximately 20 mg risperidone and 6 mg olanzapine, reported receptor occupancies are around 93–95%, respectively. Clozapine ranks third when compared using chlorpromazine equivalents.
1919) 25 August – Kurt Gottfried, Austrian-born American physicist. 2 September – Frank Drake, American astronomer and astrophysicist (Drake equation), designer of the Arecibo message (b. 1930) 9 December – Ademar José Gevaerd, Brazilian ufologist (b. 1962)
== Sports == C4 (classification), a Paralympic cycling classification C-4, professional wrestler Paul Burchill's name for his finishing move, a moonsault uranage C4, an abbreviation for a four-man Sprint Canoe, see Canoe racing C4, a term used to refer to the UEFA Intertoto Cup, a football competition (mainly used in non-English speaking countries) C4 level, a challenge square dance program at the Challenge 4 level 1. c4, or the English Opening, a chess opening
In particular, more distant atoms within corresponding features are exponentially downweighted to reduce the effects of noise introduced by loop mobility, helix torsions, and other minor structural variations. Because DALI relies on an all-to-all distance matrix, it can account for the possibility that structurally aligned features might appear in different orders within the two sequences being compared. The DALI method has also been used to construct a database known as FSSP (Fold classification based on Structure-Structure alignment of Proteins, or Families of Structurally Similar Proteins) in which all known protein structures are aligned with each other to determine their structural neighbors and fold classification. There is a searchable database based on DALI as well as a downloadable program and web search based on a standalone version known as DaliLite.
== Refining the techniques == The next development was gas chromatography (GC). Martin and Synge had predicted its principles in their 1941 paper. Erika Cremer laid the theoretical basis of GC in 1944. Austrian chemist Fritz Prior, under the direction of Erika Cremer, constructed in 1947 the first prototype of a gas chromatograph and achieved separating oxygen and carbon dioxide, in 1947 during his Ph.D. research. Beginning in 1949, Martin and Anthony T. James worked on developing GC. At his 1952 Nobel lecture, Martin announced the successful separation of a wide variety of natural compounds by GC. GC was quickly adopted since it is easy and efficient for separating organic chemicals, and new detection methods for analyzing the output were quickly developed. The thermal conductivity detector, described in 1954 by N. H. Ray, was the foundation for several other methods: the flame ionization detector by J. Harley, W. Nel, and V. Pretorius in 1958, and the electron capture detector by James Lovelock in 1958. Others introduced mass spectrometers to gas chromatography in the late 1950s. The work of Martin and Synge also set the stage for high performance liquid chromatography (HPLC), suggesting that small sorbent particles and pressure could produce fast liquid chromatography techniques. This became widely practical by the late 1960s (and the method was used to separate amino acids as early as 1960).
Sources: en.wikipedia.org
It is a synthetic peptide of 31 amino acids, built to resemble the natural incretin hormone GLP-1. Because of its size and composition it is handled analytically like other therapeutic peptides, using chromatographic and mass spectrometric methods rather than the techniques typical of small organic drugs.
The substitution at position 8 removes the site recognised by dipeptidyl peptidase-4, the enzyme that destroys the native hormone within minutes. The linked lipophilic chain then binds circulating albumin, which further limits access by degradative enzymes and reduces renal loss. Together these features lengthen the effective circulation time considerably.
It acts at the glucagon-like peptide-1 receptor, a G protein-coupled receptor that signals mainly through cyclic AMP. Activation is glucose dependent, meaning insulin release is stimulated more strongly when blood glucose is already elevated. Other tissues carrying the same receptor respond as well, which explains effects beyond glucose control.
Native GLP-1 is degraded within minutes by dipeptidyl peptidase-4 and cleared quickly. Semaglutide carries a position 8 substitution that blocks that cleavage and a fatty diacid chain that binds albumin. Together these changes extend its circulating half-life to about one week.